FIELD: chemistry.
SUBSTANCE: invention is related to the compound of general formula 1 or its tautomer or pharmaceutically acceptable salt, where W selected from N and CR4; X is selected from CH(R8), O, S, N(R8), C(=O), C(=O)O, C(=O)N(R8), OC(=O), N(R8)C(=O), C(R8)-CH and C(=R8); G1 - bicyclic or tricyclic condensed derivative of azepin, selected from general formulas 2-9
, or derivative of aniline of common formula 10
, where A1, A4, A7 and A10 are independently selected from CH2, C=O, O and NR10; A2, A3, A9, A11, A13, A14, A15, A19 and A20 are independently selected from CH and N; or A5 stands for covalent connection, and A6 represents S; or A5 stands for N=CH, and A6 represents covalent connection; A8 , A12 , A18 and A21 are independently selected from CH=CH, NH, NCH3 and S; A16 and A17 both represent CH2, or one from A16 and A17 represents CH2, and the one another is selected from C=O, CH(OH), CF2, O, SOc and NR10; Y is selected from CH=CH or S; R1 and R2 are independently selected from H, F, Cl, Br, alkyl, CF3 and group O-alkyl; R3 is selected from H and alkyl; R4-R7 are independently selected from H, F, Cl, Br, alkyl, CF3, OH and group O-alkyl; R8 is selected from H, (CH2)bR9 and (C=O)(CH2)bR9; R9 is selected from H, alkyl, possibly substituted aryl, possibly substituted heteroaryl, OH, groups O-alkyl, OC(=O)alkyl, NH2, NHalkyl, N(alkyl)2, CHO, CO2H, CO2alkyl, CONH2, CONHalkyl, CON(alkyl)2 and CN; R10 is selected from H, alkyl, group COalkyl and (CH2)dOH; R11 is selected from alkyl, (CH2)dAr, (CH2)dOH, (CH2)dNH2, group (CH2)aCOOalkyl, (CH2)dCOOH and (CH2)dOAr; R12 and R13 are independently selected from H, alkyl, F, CI, Br, CH(OCH3)2, CHF2, CF3, groups COOalkyl, CONHalkyl, (CH2)dNHCH2Ar, CON(alkyl)2, CHO, COOH, (CH2)dOH, (CH2)dNH2, N(alkyl)2, CONH(CH2)dAr and Ar; Ar is selected from possibly substituted heterocycles or possibly substituted phenyl; a is selected from 1, 2 and 3; b is selected from 1, 2, 3 and 4; c is selected from 0, 1 and 2; and d is selected from 0, 1, 2 and 3. Besides, the invention is related to pharmaceutical compound and to method for activation of vasopressin receptors of type 2.
EFFECT: compounds according to invention represent agonists of receptor of vasopressin V2, which stipulates for their application (another object of invention) for preparation of medicine for treatment of condition selected from polyuria, including polyuria, which is due to central diabetes insipidus, nocturnal enuresis of nocturnal polyurea, for control of enuresis, to postpone bladder emptying and for treatment of disorders related to bleeds.
21 cl, 228 ex
Title | Year | Author | Number |
---|---|---|---|
VASOPRESSIN V RECEPTOR ANTAGONISTS | 2005 |
|
RU2370497C2 |
NEW DIAMIDES PYRIMIDIN-4,6 OF DICARBOXYLIC ACID FOR SELECTIVE INHIBITION OF COLLAGENASES | 2003 |
|
RU2344129C2 |
DERIVATIVES OF SUBSTITUTED DIBENZOAZEPINE AND BENZODIAZEPINE, USEFUL AS INHIBITORS OF γ -SECRETASE | 2004 |
|
RU2356895C2 |
BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | 2004 |
|
RU2340617C2 |
MALONAMIDE DERIVATIVES AS γ-SECRETASE INHIBITORS | 2004 |
|
RU2330849C2 |
DERIVATIVES OF BENZIMIDAZOL INHIBITING FACTOR Xa | 2004 |
|
RU2346944C2 |
SUBSTITUTED 3-OXO-1,2,3,4-TETRAHYDROXINOXALINES, PHARMACEUTICAL COMPOSITIONS (VARIANTS), METHODS FOR PRODUCTION AND USES THEREOF | 2003 |
|
RU2251546C1 |
HETEROBICYCLIC SULPHONAMIDE DERIVATIVES FOR TREATING DIABETES | 2007 |
|
RU2407740C2 |
CONDENSED AZEPINES, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF, METHOD FOR TREATMENT BY USING INDICATED COMPOSITION | 2001 |
|
RU2259367C2 |
4-PHENOXY-NICOTANIMIDES OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDES | 2011 |
|
RU2565077C2 |
Authors
Dates
2009-06-27—Published
2005-08-18—Filed